ATE433457T1 - Angiogen-wirkende trisulfat steroide und deren verwendung - Google Patents

Angiogen-wirkende trisulfat steroide und deren verwendung

Info

Publication number
ATE433457T1
ATE433457T1 AT03788740T AT03788740T ATE433457T1 AT E433457 T1 ATE433457 T1 AT E433457T1 AT 03788740 T AT03788740 T AT 03788740T AT 03788740 T AT03788740 T AT 03788740T AT E433457 T1 ATE433457 T1 AT E433457T1
Authority
AT
Austria
Prior art keywords
trisulphate
angiogenic
steroids
compounds
provides
Prior art date
Application number
AT03788740T
Other languages
English (en)
Inventor
Aly Karsan
Michel Roberge
Raymond Andersen
Ingrid Pollet
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE433457T1 publication Critical patent/ATE433457T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03788740T 2002-12-24 2003-12-24 Angiogen-wirkende trisulfat steroide und deren verwendung ATE433457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43586402P 2002-12-24 2002-12-24
PCT/CA2003/002024 WO2004058795A1 (en) 2002-12-24 2003-12-24 Angiogenic compounds and uses thereof

Publications (1)

Publication Number Publication Date
ATE433457T1 true ATE433457T1 (de) 2009-06-15

Family

ID=32682287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03788740T ATE433457T1 (de) 2002-12-24 2003-12-24 Angiogen-wirkende trisulfat steroide und deren verwendung

Country Status (7)

Country Link
US (1) US20060014727A1 (de)
EP (1) EP1575981B1 (de)
AT (1) ATE433457T1 (de)
AU (1) AU2003292939A1 (de)
CA (1) CA2508913A1 (de)
DE (1) DE60327946D1 (de)
WO (1) WO2004058795A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8352400B2 (en) 1991-12-23 2013-01-08 Hoffberg Steven M Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore
US7904187B2 (en) 1999-02-01 2011-03-08 Hoffberg Steven M Internet appliance system and method
US20110190323A1 (en) * 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
US20120190659A1 (en) * 2009-04-22 2012-07-26 Children's Medical Center Corporation Angiogenesis inhibitors
US9546194B2 (en) * 2012-04-20 2017-01-17 Ohr Pharmaceutical, Inc. Aminosteroids for the treatment of a PTP1B associated disease
EA201891279A1 (ru) 2013-12-24 2019-01-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
EP3294298A4 (de) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
EP3316889A4 (de) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin-analoga sowie synthese und verwendungen davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US5079239A (en) * 1990-02-16 1992-01-07 Harbor Branch Oceanographic Institution, Inc. Sterol disulfates and methods of use
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis

Also Published As

Publication number Publication date
AU2003292939A1 (en) 2004-07-22
EP1575981B1 (de) 2009-06-10
DE60327946D1 (de) 2009-07-23
EP1575981A1 (de) 2005-09-21
CA2508913A1 (en) 2004-07-15
US20060014727A1 (en) 2006-01-19
WO2004058795A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
DK1719512T3 (da) Sarsasapogenin og smilagenin til behandling af cognitive dysfunktioner
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
DE60327203D1 (de) Kombination von azelastine und fluticasone
ATE552007T1 (de) Dezellularisierung und rezellularisierung von organen und geweben
DE60332475D1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
ATE416185T1 (de) Sapogenin derivate, deren synthese und verwendung
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
TW200641971A (en) High voltage metal-oxide-semiconductor transistor devices and method of making the same
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
GB2445674B (en) Compositions for the topical treatment of eczema, psoriasis and the like
DE60304788D1 (de) Granulatförmige photokatalytische Mischung für Mörtel oder Beton und ihre Verwendung
ATE433457T1 (de) Angiogen-wirkende trisulfat steroide und deren verwendung
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE289318T1 (de) 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe
BR0308660A (pt) C-17 espirolactonização e 6,7 oxidação de esteróides
DK1467762T3 (da) Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
NO20033321D0 (no) Androgeniske 7-substituerte 11-halogensteroider
CY1106754T1 (el) Σκευασματα τιμπολονης
PT1196428E (pt) Esteroides substituidos com 11 beta-aril-17, 17-espirotiolano
ATE321760T1 (de) N-aryl-2-oxazolidinone und deren derivate
DE60323513D1 (de) Oberflächenmodifizierte plexifilamentarstrukturen und zusammensetzungen dafür
NO20030606D0 (no) Modifisert gj¶r og anvendelser derav, n¶rmere bestemt for fremstilling avsteroidderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties